The global breast biopsy devices market size was estimated to be USD 1.84 billion in 2023 and is expected to reach at USD 5.50 billion by 2033 with a CAGR of 10.46% during the forecast period 2023-2033. Increasing prevalence of breast cancer, surge in number of breast cancer screening procedures, rising demand for early disease diagnosis & treatment, growing research & development activities, increasing approvals by regulatory bodies, surge in initiatives such as mergers, acquisitions, partnerships, & collaborations within market players, and rising launch of advanced biopsy products are some of the key factors boosting the market growth.
Rising launch of advanced biopsy products is predicted to boost the market growth during the forecast period. Radiologists and surgeons may be able to execute breast treatments more precisely, easily, and conveniently if they use a sophisticated biopsy method. Players now have several opportunities to enter this market and dominate it with cutting-edge technologies. For instance, in May 2023, Argon Medical Devices has introduced the latest addition to its soft tissue biopsy product lineup in the United States, known as the SuperCore Advantage semi-automatic biopsy instrument. This next-generation biopsy tool is designed to enhance the amount of tissue samples it can obtain, potentially improving the accuracy of diagnostic procedures by collecting a greater tissue volume.
By type, biopsy needles was the highest revenue-grossing segment in the global breast biopsy devices market in 2022 owing to the rising technological advancements, increasing new product launches, surge in government initiatives supporting breast cancer screening programs & awareness campaigns, and surge in clinical trials procedures. For instance, in August 2022, TransMed7, LLC has reported the successful completion of the inaugural clinical cases involving the ultimate commercial production model of the Sparrow device. This device is part of the newly introduced SpeedBird family of vacuum-assisted, Single Insertion / Multiple Collection (SIMC) Breast Biopsy devices. The procedures were carried out by Dr. Edgar Staren, a renowned surgeon and former President of the American Society of Breast Surgeons (ASBrS). Additionally, guidance systems is predicted to grow at fastest CAGR during the forecast period owing to the growing technological advancements, increasing investment in research & development activities, and rising launch of new products.
By procedure, liquid breast biopsy was the highest revenue-grossing segment in the global breast biopsy devices market in 2022 owing to the rising investments by major market players, increasing research & development activities, surge in number of clinical trial procedures, and growing approvals by regulatory bodies. Additionally, needle breast biopsy is predicted to grow at fastest CAGR during the forecast period owing to the growing technological advancements and increasing launch of advanced systems. For instance, in August 2022, Mammotome, a prominent figure in the field of breast care and the originator of vacuum-assisted breast biopsy technology, is excited to present the Mammotome RevolveTM EX Dual Vacuum-Assisted Breast Biopsy System. This innovative device marks the first of its kind, tailored for the removal of benign breast lesions, and offers a significant speed advantage, being twice as fast as conventional vacuum-assisted breast biopsy systems.
By technique, image-guided biopsy was the highest revenue-grossing segment in the global breast biopsy devices market in 2022 owing to the the improved localization accuracy of irregular or abnormal masses made possible by image-guided operations, which is superior to the accuracy attained by non-image-guided methods, increasing demand for advanced image guided systems, and growing developments in molecular imaging-related technologies. For instance, in March 2022, At the University of Notre Dame, the NearWave Imager, an innovative imaging tool for the detection and tracking of breast cancer, has reached the prototype development stage. Additionally, liquid biopsy is predicted to grow at fastest CAGR during the forecast period owing to the growing demand for non-invasive treatment procedures, increasing prevalence of breast cancer, and rising introduction of advanced products.
By application, early cancer screening was the highest revenue-grossing segment in the global breast biopsy devices market in 2022 owing to the, increasing prevalence of breast cancer, rising demand for early-stage cancer diagnosis, real-time surveillance of recurrences & evaluation of disease progression, rising initiatives by market players. For instance, in March 2022, Hologic Inc., a pioneering medical technology firm with a strong emphasis on enhancing women's healthcare, has inaugurated its Innovation Center in Aix-en-Provence, France. This newly established complex serves as a commercial office and also functions as a facility dedicated to training and research and development. Its primary objective is to provide comprehensive support for Hologic's ultrasound, interventional, and surgical solutions throughout the entire spectrum of breast healthcare. Additionally, therapy selection is predicted to grow at fastest CAGR during the forecast period owing to the growing demand for the treatment of breast cancer, increasing awareness regarding breast cancer, surge in supportive government initiatives for breast cancer care & treatment, and surge in launch of innovative products.
By end-user, hospitals & clinics was the highest revenue-grossing segment in the global breast biopsy devices market in 2022 owing to the surge in number of breast diagnostic procedures conducted in hospitals, rising preference of hospitals for the automation & digitization of radiology patient workflow, growing adoption of technologically advanced systems to enhance the quality of patient care, and increasing initiatives by leading market players. For instance, in March 2022, Hologic Inc., a forward-thinking medical technology firm with a primary focus on enhancing women's health, has inaugurated its Innovation Centre in Aix-en-Provence, France. This new facility, serving as a commercial office and dedicated to training and research & development, is intended to bolster Hologic's offerings in ultrasound, interventional, and surgical solutions within the realm of breast healthcare. Additionally, pharmaceutical & biotechnology companies is predicted to grow at fastest CAGR during the forecast period owing to the rising focus on development of innovative products, increasing technological advancements, and growing launch of innovative products.
North America region is anticipated for the highest revenue share during the forecast period owing to the rising technological advancements, increasing prevalence of breast cancer, surge in favorable reimbursement scenarios, and growing introduction of technologically advanced products. For instance, in January 2022, DefineMBC, a liquid biopsy from Epic Sciences, combines cell-based and cell-free evaluations to offer a thorough picture of metastatic breast cancer in cases when a tissue biopsy is impractical. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the rising prevalence of breast cancer, growing focus on development of advanced technologies, and increasing approvals by regulatory bodies. For instance, in September 2022, NeoDynamics has obtained clearance from the US FDA through the 510(k) process for its NeoNavia pulse biopsy system. NeoNavia, designed for breast biopsies, employs a patented pulse technology to ensure precise and controlled needle insertion, a technique developed through research conducted at Karolinska Institutet.
Rising launch of advanced biopsy products is predicted to boost the market growth during the forecast period. Radiologists and surgeons may be able to execute breast treatments more precisely, easily, and conveniently if they use a sophisticated biopsy method. Players now have several opportunities to enter this market and dominate it with cutting-edge technologies. For instance, in May 2023, Argon Medical Devices has introduced the latest addition to its soft tissue biopsy product lineup in the United States, known as the SuperCore Advantage semi-automatic biopsy instrument. This next-generation biopsy tool is designed to enhance the amount of tissue samples it can obtain, potentially improving the accuracy of diagnostic procedures by collecting a greater tissue volume.
By type, biopsy needles was the highest revenue-grossing segment in the global breast biopsy devices market in 2022 owing to the rising technological advancements, increasing new product launches, surge in government initiatives supporting breast cancer screening programs & awareness campaigns, and surge in clinical trials procedures. For instance, in August 2022, TransMed7, LLC has reported the successful completion of the inaugural clinical cases involving the ultimate commercial production model of the Sparrow device. This device is part of the newly introduced SpeedBird family of vacuum-assisted, Single Insertion / Multiple Collection (SIMC) Breast Biopsy devices. The procedures were carried out by Dr. Edgar Staren, a renowned surgeon and former President of the American Society of Breast Surgeons (ASBrS). Additionally, guidance systems is predicted to grow at fastest CAGR during the forecast period owing to the growing technological advancements, increasing investment in research & development activities, and rising launch of new products.
By procedure, liquid breast biopsy was the highest revenue-grossing segment in the global breast biopsy devices market in 2022 owing to the rising investments by major market players, increasing research & development activities, surge in number of clinical trial procedures, and growing approvals by regulatory bodies. Additionally, needle breast biopsy is predicted to grow at fastest CAGR during the forecast period owing to the growing technological advancements and increasing launch of advanced systems. For instance, in August 2022, Mammotome, a prominent figure in the field of breast care and the originator of vacuum-assisted breast biopsy technology, is excited to present the Mammotome RevolveTM EX Dual Vacuum-Assisted Breast Biopsy System. This innovative device marks the first of its kind, tailored for the removal of benign breast lesions, and offers a significant speed advantage, being twice as fast as conventional vacuum-assisted breast biopsy systems.
By technique, image-guided biopsy was the highest revenue-grossing segment in the global breast biopsy devices market in 2022 owing to the the improved localization accuracy of irregular or abnormal masses made possible by image-guided operations, which is superior to the accuracy attained by non-image-guided methods, increasing demand for advanced image guided systems, and growing developments in molecular imaging-related technologies. For instance, in March 2022, At the University of Notre Dame, the NearWave Imager, an innovative imaging tool for the detection and tracking of breast cancer, has reached the prototype development stage. Additionally, liquid biopsy is predicted to grow at fastest CAGR during the forecast period owing to the growing demand for non-invasive treatment procedures, increasing prevalence of breast cancer, and rising introduction of advanced products.
By application, early cancer screening was the highest revenue-grossing segment in the global breast biopsy devices market in 2022 owing to the, increasing prevalence of breast cancer, rising demand for early-stage cancer diagnosis, real-time surveillance of recurrences & evaluation of disease progression, rising initiatives by market players. For instance, in March 2022, Hologic Inc., a pioneering medical technology firm with a strong emphasis on enhancing women's healthcare, has inaugurated its Innovation Center in Aix-en-Provence, France. This newly established complex serves as a commercial office and also functions as a facility dedicated to training and research and development. Its primary objective is to provide comprehensive support for Hologic's ultrasound, interventional, and surgical solutions throughout the entire spectrum of breast healthcare. Additionally, therapy selection is predicted to grow at fastest CAGR during the forecast period owing to the growing demand for the treatment of breast cancer, increasing awareness regarding breast cancer, surge in supportive government initiatives for breast cancer care & treatment, and surge in launch of innovative products.
By end-user, hospitals & clinics was the highest revenue-grossing segment in the global breast biopsy devices market in 2022 owing to the surge in number of breast diagnostic procedures conducted in hospitals, rising preference of hospitals for the automation & digitization of radiology patient workflow, growing adoption of technologically advanced systems to enhance the quality of patient care, and increasing initiatives by leading market players. For instance, in March 2022, Hologic Inc., a forward-thinking medical technology firm with a primary focus on enhancing women's health, has inaugurated its Innovation Centre in Aix-en-Provence, France. This new facility, serving as a commercial office and dedicated to training and research & development, is intended to bolster Hologic's offerings in ultrasound, interventional, and surgical solutions within the realm of breast healthcare. Additionally, pharmaceutical & biotechnology companies is predicted to grow at fastest CAGR during the forecast period owing to the rising focus on development of innovative products, increasing technological advancements, and growing launch of innovative products.
North America region is anticipated for the highest revenue share during the forecast period owing to the rising technological advancements, increasing prevalence of breast cancer, surge in favorable reimbursement scenarios, and growing introduction of technologically advanced products. For instance, in January 2022, DefineMBC, a liquid biopsy from Epic Sciences, combines cell-based and cell-free evaluations to offer a thorough picture of metastatic breast cancer in cases when a tissue biopsy is impractical. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the rising prevalence of breast cancer, growing focus on development of advanced technologies, and increasing approvals by regulatory bodies. For instance, in September 2022, NeoDynamics has obtained clearance from the US FDA through the 510(k) process for its NeoNavia pulse biopsy system. NeoNavia, designed for breast biopsies, employs a patented pulse technology to ensure precise and controlled needle insertion, a technique developed through research conducted at Karolinska Institutet.
Segmentation: Breast Biopsy Devices Market Report 2022-2033
Breast Biopsy Devices Market Analysis & Forecast by Type 2022-2033 (Revenue USD Bn)
- Localization Wires
- Biopsy Needles
- Biopsy Tables
- Guidance Systems
- Liquid Biopsy Instruments
- Assay Kits
- Others
Breast Biopsy Devices Market Analysis & Forecast by Procedure 2022-2033 (Revenue USD Bn)
Needle Breast Biopsy
- Core Needle Biopsy (CNB)
- Fine Needle Aspiration Biopsy
- Vacuum Assisted Biopsy
Liquid Breast Biopsy
- Circulating Tumor DNA (CtDNA)
- Circulating Tumor Cells
- Others
Open Surgical Breast Biopsy
- Incisional
- Excisional
Breast Biopsy Devices Market Analysis & Forecast by Technique 2022-2033 (Revenue USD Bn)
Liquid Biopsy
- PCR-Based Biopsy
- NGS-Based Biopsy
- Microarray-Based Biopsy
Image-Guided Biopsy
- Mammography-Guided Stereotactic Biopsy
- MRI-Guided Biopsy
- Ultrasound-Guided Biopsy
- Others
Breast Biopsy Devices Market Analysis & Forecast by Application 2022-2033 (Revenue USD Bn)
- Therapy Selection
- Treatment Monitoring
- Recurrence Monitoring
- Early Cancer Screening
Breast Biopsy Devices Market Analysis & Forecast by End-user 2022-2033 (Revenue USD Bn)
- Hospitals & Clinics
- Pharmaceutical & Biotechnology Companies
- Research Laboratories
Breast Biopsy Devices Market Analysis & Forecast by Region 2022-2033 (Revenue USD Bn)
North America
- U.S.
- Canada
Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Breast Biopsy Devices Market: Type Estimates & Trend Analysis
8. Breast Biopsy Devices Market: Procedure Estimates & Trend Analysis
9. Breast Biopsy Devices Market: Technique Estimates & Trend Analysis
10. Breast Biopsy Devices Market: Application Estimates & Trend Analysis
11. Breast Biopsy Devices Market: End-user Estimates & Trend Analysis
12. Regional Market Analysis
13. North America Breast Biopsy Devices Market
14. Europe Global Breast Biopsy Devices Market
15. Asia Pacific Global Breast Biopsy Devices Market
16. Latin America Global Breast Biopsy Devices Market
17. MEA Global Breast Biopsy Devices Market
18. Competitor Analysis
19. Company Profiles
Companies Mentioned
- Varian Medical Systems Inc.
- Argon Medical Devices
- Danaher Corporation
- Menarini-Silicon Biosystems
- Qiagen
- Merit Medical Systems
- Planmed Oy
- Sterylab S.R.L.
- Biocept Inc.
- Hologic Inc
- Bio-Rad Laboratories Inc.
- Medtronic
- Exact Sciences Corporation
- F. Hoffmann-La Roche Ltd
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 145 |
| Published | October 2023 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 1.84 Billion |
| Forecasted Market Value ( USD | $ 5.5 Billion |
| Compound Annual Growth Rate | 10.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 14 |
